Iron modulates interferon-gamma effects in the human myelomonocytic cell line THP-1.
This investigation demonstrates that low concentrations (25 microM) of free and transferrin-bound iron reduce the efficiency of the interferon-gamma (IFN-gamma) signal in the human myelomonocytic cell line THP-1, as seen by decreased production of neopterin, reduced degradation of tryptophan, and impaired expression of major histocompatibility complex (MHC) class II antigens. This inhibitory effect of iron, which is not due to an enhanced cytotoxicity towards THP-1 cells, is increased by enhancement of iron concentrations in a dose-dependent relationship and can be partially reversed by increasing amounts of the cytokine. The iron-mediated inhibition of the effects of IFN-gamma is fully reversed when iron is administered concomitantly with equimolar concentrations of the iron chelator deferoxamine. Furthermore, deferoxamine alone is even able to enhance the efficiency of the IFN-gamma signal. Our data provide evidence that there is an inverse correlation between the intracellular amount of iron, which is not bound to ferritin, and the activity of the IFN-gamma signal. This suggests that iron withholding by the immune cells in the course of inflammatory disorders may also contribute to the enhancement of the cytopathic effect of IFN-gamma. This speculation is confirmed by the observation of high concentrations of immune activation markers such as IFN-gamma and neopterin and low serum iron levels in patients with hypoferric anemia in the course of chronic inflammation.
Weiss
G
G
Institute for Medical Chemistry and Biochemistry, University of Innsbruck, Austria.
Fuchs
D
D
Hausen
A
A
Reibnegger
G
G
Werner
E R
ER
Werner-Felmayer
G
G
Wachter
H
H
D001708:Biopterins / Q000031:analogs & derivatives / Q000378:metabolism; D049308:Dioxygenases; D004305:Dose-Response Relationship, Drug; D004790:Enzyme Induction / Q000187:drug effects; D006136:GTP Cyclohydrolase / Q000378:metabolism; D000949:Histocompatibility Antigens Class II / Q000187:drug effects; D006801:Humans; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase; D007371:Interferon-gamma / Q000187:drug effects / Q000502:physiology*; D007501:Iron / Q000494:pharmacology*; D007951:Leukemia, Myeloid / Q000473:pathology*; D019798:Neopterin; D010105:Oxygenases / Q000378:metabolism; D014364:Tryptophan / Q000378:metabolism; D014407:Tumor Cells, Cultured / Q000187:drug effects*
D000949:Histocompatibility Antigens Class II; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase; D001708:Biopterins; D019798:Neopterin; D007371:Interferon-gamma; D014364:Tryptophan; D007501:Iron; D010105:Oxygenases; D049308:Dioxygenases; D006136:GTP Cyclohydrolase